These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8103158)

  • 41. Acute cytomegalovirus infection in AIDS patients with CD4 counts above 100 x 10(6) cells/l following combination antiretroviral therapy including protease inhibitors.
    Gilquin J; Piketty C; Thomas V; Gonzales-Canali G; Belec L; Kazatchkine MD
    AIDS; 1997 Nov; 11(13):1659-60. PubMed ID: 9365778
    [No Abstract]   [Full Text] [Related]  

  • 42. New concepts in the mechanisms of CD4+ lymphocyte depletion in AIDS, and the influence of opportunistic infections.
    Gougeon ML; Montagnier L
    Res Microbiol; 1992 May; 143(4):362-8. PubMed ID: 1360691
    [No Abstract]   [Full Text] [Related]  

  • 43. Interferon-gamma and tumour necrosis factor-alpha production by CD4+ T and CD8+ T lymphocytes in AIDS patients with tuberculosis.
    de Castro Cunha RM; Kallas EG; Rodrigues DS; Nascimento Burattini M; Salomao R
    Clin Exp Immunol; 2005 Jun; 140(3):491-7. PubMed ID: 15932510
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Isoniazid TB prophylaxis effective in drug users with HIV.
    J Int Assoc Physicians AIDS Care; 1996 Jun; 2(6):51. PubMed ID: 11363698
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The double burden of HIV infection and tuberculosis in sub-Saharan Africa.
    Msamanga GI; Fawzi WW
    N Engl J Med; 1997 Sep; 337(12):849-51. PubMed ID: 9295244
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.
    Hoover DR; Saah AJ; Bacellar H; Phair J; Detels R; Anderson R; Kaslow RA
    N Engl J Med; 1993 Dec; 329(26):1922-6. PubMed ID: 7902536
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness.
    Snyder DC; Paz EA; Mohle-Boetani JC; Fallstad R; Black RL; Chin DP
    Am J Respir Crit Care Med; 1999 Jul; 160(1):178-85. PubMed ID: 10390397
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Primary chemoprevention of tuberculosis in HIV-infected patients in non-industrialized countries].
    Anglaret X; Dabis F; Batungwanayo J; Perronne C; Taelman H; Bonard D; Sylla-Koko F; Leroy V; Van de Perre P; Vildé JL; Salamon R
    Sante; 1997; 7(2):89-94. PubMed ID: 9273126
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Survival in a cohort of human immunodeficiency virus-infected tuberculosis patients in New York City. Implications for the expansion of the AIDS case definition.
    Stoneburner R; Laroche E; Prevots R; Singh T; Blum S; Terry P; Reatrice S; Adler J
    Arch Intern Med; 1992 Oct; 152(10):2033-7. PubMed ID: 1358042
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients.
    Casado JL; Moreno S; Fortún J; Antela A; Quereda C; Navas E; Moreno A; Dronda F
    Clin Infect Dis; 2002 Feb; 34(3):386-9. PubMed ID: 11753825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neonatal pyridoxine responsive convulsions due to isoniazid therapy.
    McKenzie SA; Macnab AJ; Katz G
    Arch Dis Child; 1976 Jul; 51(7):567-8. PubMed ID: 1085609
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New UK guidance on the prevention and control of transmission of HIV related and drug resistant tuberculosis.
    Commun Dis Rep CDR Wkly; 1999 Feb; 9(6):49. PubMed ID: 10024752
    [No Abstract]   [Full Text] [Related]  

  • 53. Mucosal co-infections and HIV-1 transmission and pathogenesis.
    Schust DJ; Quayle AJ; Amedee AM
    Curr HIV Res; 2012 Apr; 10(3):195-201. PubMed ID: 22497695
    [No Abstract]   [Full Text] [Related]  

  • 54. Undernutrition, nutritionally acquired immunodeficiency, and tuberculosis control.
    Bhargava A
    BMJ; 2016 Oct; 355():i5407. PubMed ID: 27733343
    [No Abstract]   [Full Text] [Related]  

  • 55. Tuberculosis control in the face of the HIV epidemic.
    Harries AD; Nyirenda T; Banerjee A; Salaniponi FM; Boeree MJ
    Trop Doct; 1998 Oct; 28(4):243-5. PubMed ID: 9803856
    [No Abstract]   [Full Text] [Related]  

  • 56. Why the treatment with Reprimun could be efficient for tuberculosis prevention in HIV infected individuals.
    Păunescu E
    Pneumoftiziologia; 1992; 41(1):45-6. PubMed ID: 1299399
    [No Abstract]   [Full Text] [Related]  

  • 57. Chemoprophylaxis in tuberculosis and HIV infection.
    Walley J; Porter J
    BMJ; 1995 Jun; 310(6995):1621-2. PubMed ID: 7795439
    [No Abstract]   [Full Text] [Related]  

  • 58. Isoniazid prophylaxis of tuberculosis.
    Nardini S
    Monaldi Arch Chest Dis; 1994 Feb; 49(1):88. PubMed ID: 8193630
    [No Abstract]   [Full Text] [Related]  

  • 59. Tuberculosis and HIV: time for an intensified response.
    Ghebreyesus TA; Kazatchkine M; Sidibé M; Nakatani H
    Lancet; 2010 May; 375(9728):1757-8. PubMed ID: 20488527
    [No Abstract]   [Full Text] [Related]  

  • 60. Tuberculosis and HIV infection.
    Markus MB
    Lancet; 1993 Sep; 342(8872):677. PubMed ID: 8103160
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.